PHUSE 2024 SDE, Gurgaon: 16 Mar 2024
Coming soon
ISCR 2024: 01-03 Feb 2024
Attending ISCR 2024 in Hyderabad has been an amazing experience. This international conference not only provided a dynamic platform to connect with industry leaders and potential collaborators but also greatly benefited by engaging discussions. It fostered meaningful relationships, opening doors for the exchange of ideas and collaborative opportunities that would shape the future trajectory of professional growth.
IL-6 receptor antagonist
Unravelling the potential of IL-6 Receptor Antagonists: A ray of hope for the treatment of Rheumatoid Arthritis
Rheumatoid arthritis (RA) can be difficult to live with because of the constant inflammation that damages joints and general health. Interleukin 6 (IL-6) receptor antagonists provide a ray of hope in the constantly changing field of RA treatment. This blog post will explain what these biologicals are, how they work differently from conventional disease-modifying antirheumatic drugs (DMARDs), and discuss some of the newest IL-6 receptor antagonists that are gaining popularity in RA treatment.
Understanding IL-6 Receptor Antagonists
IL-6, is a cytokine that is essential to the inflammatory cascade linked to RA. A class of biologic medications known as IL-6 receptor antagonists is made to obstruct the IL-6 signalling pathway, which in turn reduces joint damage and upsets the inflammatory response.
Advantages over DMARDs
IL-6 receptor antagonists target a particular cytokine, providing a more focused and accurate treatment than DMARDs, which inhibit the immune system more widely. This selectivity reduces immune-suppressive side effects, which are a common worry with conventional RA therapies.
Benefits of IL-6 Receptor Antagonists
- Decreased joint inflammation: By successfully reducing joint inflammation, IL-6 receptor antagonists relieve pain and stiffness in the joints.
- Enhanced functionality: These biologicals help to enhance joint function by reducing inflammation, which enables patients to regain mobility and lead more active lives.
- Delaying joint degradation: Studies have indicated that focusing on the IL-6 pathway may be able to slow down or stop the progression of joint degradation, eventually maintaining joint integrity.
- Improved quality of Life: By specifically targeting IL-6, individuals with RA may have a significant improvement in their overall quality of life as their symptoms are better controlled and there are less systemic side effects.
Latest FDA approved IL-6 Receptor Antagonists
- Actemra (tocilizumab)
- Arava (Leflunomide)
- Azulfidine (sulfasalazine)
- Duexis (ibuprofen and famotidine)
- Enbrel (etanercept)
- Humira (adalimumab)
- Kevzara (sarilumab)
- Kineret (anakinra)
- Mobic (meloxicam) Tablets
- Naprelan (naproxen sodium)
- Olumiant (baricitinib)
- Orencia (abatacept)
- Rayos (prednisone) delayed-release tablets
- Remicade (infliximab)
- Rinvoq (upadacitinib)
- Rituxan (rituximab)
- Simponi, Simponi Aria (golimumab)
- Xeljanz (tofacitinib)
Conclusion
When compared to conventional DMARDs, IL-6 receptor antagonists provide tailored treatment with better results, marking a revolutionary advancement in the management of RA. These biologicals open the door to more individualized and successful treatment approaches as research into the intricacies of RA progresses, giving patients dealing with rheumatoid arthritis fresh hope. The best course of action for your particular needs will always be determined after consulting with your healthcare professional.
Barcitinib – FDA approval
FDA approves first biosimilar to Actemra to treat adult and paediatric arthritis
Tofidence (tocilizumab-bavi) is FDA-approved as a biosimilar to Actemra. This medication suppresses the immune system by targeting specific inflammatory proteins as an IL-6 receptor antagonist. Tofidence is approved for the same indications as U.S.-licensed Actemra: adult rheumatoid arthritis, polyarticular and systemic juvenile idiopathic arthritis.
Rheumatoid arthritis as a disease
RA is an autoimmune and inflammatory disease in which your immune system mistakenly assaults healthy cells, causing inflammation (painful swelling) in the affected areas. RA mostly targets joints and can affect multiple joints.
Both polyarticular and systemic juvenile idiopathic arthritis cause inflammation of joints where two bones touch. Swollen, painful joints may be heated. Polyarticular arthritis affects numerous joints, while systemic arthritis can cause fever, rash, lymph node enlargement, and spleen or liver enlargement.
Approval Information
A biosimilar is a biological product that is substantially comparable to an FDA-approved reference product and has no clinically relevant deviations. This means biosimilars are as safe and effective as reference products. All biological products must pass the FDA’s strict clearance process.
After a thorough scientific review, it was revealed that Tofidence is comparable to Actemra and has no clinically significant differences. This evidence comprised thorough physicochemical and biological experiments to compare the products for analysis.
Multiple lots of each product were examined over a wide range of product quality qualities, and the results showed that Tofidence and Actemra have identical structural and functional features, including safety and efficacy aspects. A trial in methotrexate-uncontrolled rheumatoid arthritis patients showed identical effectiveness, safety, and immunogenicity outcomes. Overall, these findings supported FDA approval of Tofidence as an Actemra biosimilar.
Safety information
Upper respiratory tract infections, nasopharyngitis (common cold), headache, hypertension, raised ALT, and injection site responses are the most prevalent tocilizumab side effects.
See full prescribing information for additional information on risks associated with #Tofidence.
Analytical & Instructive Documentation
Core Support
- Standard Operating Procedures with abstemious blend of local practices and PQS requirements
- Guiding Documents and Work Instructions, in compliance to global guidance like ICH, USP, EDQM, AOAC, ISO, NIST etc.
- Computerized System Validation: IQ/ OQ/PQ/ Validation protocols, specifications and reports, ER-ES compliance assessment, Risk assessments, Data Integrity Assessments, Trace matrixing etc.
- Analytical test method validation and reports
- Drug product and API specifications
- Standard test procedures
- Stability trending
- Elemental impurity assessment reports in compliance to ICH Q3D and USP <232> and <233>
- Genotoxic impurity assessment reports as per ICH M7
- Nitrosamine impurity assessment reports
- Change management
- Investigation protocols and reports
- Corrective and preventive action management